Zoetis (ZTS) Getting Somewhat Positive Media Coverage, Analysis Finds
Headlines about Zoetis (NYSE:ZTS) have been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zoetis earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.8758728000924 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have effected Accern’s rankings:
- Zoetis Inc., (NYSE: ZTS) – Beta Factor to Watch – Stock Watch (stocksnewstimes.com)
- Do What Insiders Does: Zoetis Inc. (ZTS), The Bank of New York … – Market Movers (financialqz.com)
- Zacks: Analysts Expect Zoetis Inc (ZTS) Will Announce Quarterly Sales of $1.40 Billion (americanbankingnews.com)
- Do What Insiders Does: Zoetis Inc. (ZTS), The Bank of New York Mellon Corporation (BK) – Market Movers (financialqz.com)
- Zoetis Inc (ZTS) Expected to Announce Earnings of $0.66 Per Share (americanbankingnews.com)
Zoetis (ZTS) traded down $0.56 during trading hours on Tuesday, hitting $73.27. 4,754,172 shares of the stock were exchanged, compared to its average volume of 2,873,663. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $35,320.00, a price-to-earnings ratio of 38.56, a PEG ratio of 1.69 and a beta of 1.07. Zoetis has a twelve month low of $52.00 and a twelve month high of $80.13.
ZTS has been the subject of a number of research reports. BMO Capital Markets restated a “hold” rating and set a $65.00 target price on shares of Zoetis in a research report on Thursday, November 2nd. Cowen set a $80.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a research report on Wednesday, November 29th. UBS Group restated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Finally, Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $73.72.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.